BARKLEY PMHNP 2026 |
-QUESTION MEGA EXAM BANK
COMPREHENSIVE PRACTICE
LATEST MOCK PRACTICE SET
249 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
BARKLEY PMHNP 2026 | -QUESTION MEGA EXAM BANK COMPREHENSIVE PRACTICE EXAMS &
ADVANCED CASE SCENARIOS. It contains 249 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 249 Questions
Foundations - Application - Barkley Pmhnp 2026 - MEGA BANK Comprehensive Exams & Advanced
CASE Scenarios Psychiatric-mental Health Nurse Practitioner Graduate Pmhnp Program
All answers with rationales
,Table of Contents
Section A - Foundations OF Section B - Neurobiology AND
Psychiatric Mental Health Nursing Psychopharmacology
Questions 1 to 63 Questions 64 to 126
Section C - Assessment Diagnosis Section D - Therapeutic
AND Treatment Planning Communication AND THE
Questions 127 to 189 Nurse-patient Relationship
Questions 190 to 249
,Section A - Foundations OF Psychiatric Mental Health
Nursing
Q1.
A patient with treatment-resistant depression has failed adequate trials of two SSRIs and
one SNRI. Current medication includes venlafaxine 225 mg/day. Which augmentation
strategy is most supported by evidence for this scenario, considering both efficacy and
tolerability?
A. Add aripiprazole 2-10 mg/day B. Switch to phenelzine 45 mg/day
C. Add buspirone 30 mg/day D. Augment with liothyronine 25 mcg/day
Correct: A - Add aripiprazole 2-10 mg/day
Rationale:Aripiprazole is FDA-approved for adjunctive treatment of MDD and has strong
evidence for efficacy in treatment-resistant depression. Phenelzine, while effective, requires
dietary restrictions and has significant safety concerns. Buspirone and liothyronine have
weaker evidence and are not first-line augmentation strategies.
Q2.
Which of the following best describes the mechanism of action of brexpiprazole in treating
schizophrenia?
A. Partial agonism at D2 and 5-HT1A B. Full antagonism at D2 and 5-HT2A
receptors with antagonism at 5-HT2A receptors
receptors
C. Dopamine D2 partial agonism with D. Selective serotonin reuptake inhibition
5-HT2A antagonism and norepinephrine with weak D2 antagonism
reuptake inhibition
Correct: A - Partial agonism at D2 and 5-HT1A receptors with antagonism at 5-HT2A
receptors
Rationale:Brexpiprazole is a serotonin-dopamine activity modulator with partial agonism at
D2 and 5-HT1A receptors and antagonism at 5-HT2A receptors. Option B describes typical
antipsychotics, C describes aripiprazole, and D describes antidepressants like trazodone.
Q3.
A patient with bipolar I disorder, currently euthymic on lithium 900 mg/day, presents with a
serum lithium level of 1.1 mEq/L and creatinine clearance of 45 mL/min. Which adjustment
is most appropriate?
Page 3
, Section A - Foundations OF Psychiatric Mental Health Nursing
A. Continue current dose and monitor renal B. Reduce lithium dose to 600 mg/day and
function monthly recheck level in 5 days
C. Discontinue lithium and start valproate D. Increase lithium dose to 1200 mg/day to
500 mg BID achieve therapeutic level
Correct: B - Reduce lithium dose to 600 mg/day and recheck level in 5 days
Rationale:With reduced creatinine clearance, lithium excretion is impaired, increasing toxicity
risk. Dose reduction is indicated. Continuing the current dose risks toxicity; discontinuing is
unnecessary; increasing dose is dangerous. Valproate could be considered if lithium is not
tolerated, but dose reduction is the first step.
Q4.
In the context of cognitive-behavioral therapy for panic disorder, which intervention is
primarily aimed at reducing interoceptive avoidance?
A. Creating a fear hierarchy of external B. Teaching diaphragmatic breathing for
situations relaxation
C. Conducting repeated exposure to feared D. Challenging catastrophic
bodily sensations misinterpretations of palpitations
Correct: C - Conducting repeated exposure to feared bodily sensations
Rationale:Interoceptive exposure involves repeated, systematic exposure to internal bodily
sensations (e.g., hyperventilation, spinning) to reduce fear of these sensations. Option A
targets situational avoidance, B is a relaxation technique, and D is cognitive restructuring,
which addresses misinterpretations but not avoidance directly.
Q5.
A patient with generalized anxiety disorder has not responded to first-line
pharmacotherapy. Which combination of psychotherapy and medication is most
supported by evidence for refractory cases?
A. Acceptance and commitment therapy B. Cognitive-behavioral therapy plus
plus buspirone pregabalin
C. Mindfulness-based stress reduction plus D. Interpersonal therapy plus duloxetine
hydroxyzine
Correct: B - Cognitive-behavioral therapy plus pregabalin
Rationale:CBT and pregabalin have strong evidence for GAD, including in refractory cases.
ACT and buspirone have less robust evidence; MBSR and hydroxyzine are less effective; IPT
is not indicated for GAD, and duloxetine is a first-line but not specifically for refractory cases
with CBT.
Page 4
-QUESTION MEGA EXAM BANK
COMPREHENSIVE PRACTICE
LATEST MOCK PRACTICE SET
249 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
BARKLEY PMHNP 2026 | -QUESTION MEGA EXAM BANK COMPREHENSIVE PRACTICE EXAMS &
ADVANCED CASE SCENARIOS. It contains 249 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 249 Questions
Foundations - Application - Barkley Pmhnp 2026 - MEGA BANK Comprehensive Exams & Advanced
CASE Scenarios Psychiatric-mental Health Nurse Practitioner Graduate Pmhnp Program
All answers with rationales
,Table of Contents
Section A - Foundations OF Section B - Neurobiology AND
Psychiatric Mental Health Nursing Psychopharmacology
Questions 1 to 63 Questions 64 to 126
Section C - Assessment Diagnosis Section D - Therapeutic
AND Treatment Planning Communication AND THE
Questions 127 to 189 Nurse-patient Relationship
Questions 190 to 249
,Section A - Foundations OF Psychiatric Mental Health
Nursing
Q1.
A patient with treatment-resistant depression has failed adequate trials of two SSRIs and
one SNRI. Current medication includes venlafaxine 225 mg/day. Which augmentation
strategy is most supported by evidence for this scenario, considering both efficacy and
tolerability?
A. Add aripiprazole 2-10 mg/day B. Switch to phenelzine 45 mg/day
C. Add buspirone 30 mg/day D. Augment with liothyronine 25 mcg/day
Correct: A - Add aripiprazole 2-10 mg/day
Rationale:Aripiprazole is FDA-approved for adjunctive treatment of MDD and has strong
evidence for efficacy in treatment-resistant depression. Phenelzine, while effective, requires
dietary restrictions and has significant safety concerns. Buspirone and liothyronine have
weaker evidence and are not first-line augmentation strategies.
Q2.
Which of the following best describes the mechanism of action of brexpiprazole in treating
schizophrenia?
A. Partial agonism at D2 and 5-HT1A B. Full antagonism at D2 and 5-HT2A
receptors with antagonism at 5-HT2A receptors
receptors
C. Dopamine D2 partial agonism with D. Selective serotonin reuptake inhibition
5-HT2A antagonism and norepinephrine with weak D2 antagonism
reuptake inhibition
Correct: A - Partial agonism at D2 and 5-HT1A receptors with antagonism at 5-HT2A
receptors
Rationale:Brexpiprazole is a serotonin-dopamine activity modulator with partial agonism at
D2 and 5-HT1A receptors and antagonism at 5-HT2A receptors. Option B describes typical
antipsychotics, C describes aripiprazole, and D describes antidepressants like trazodone.
Q3.
A patient with bipolar I disorder, currently euthymic on lithium 900 mg/day, presents with a
serum lithium level of 1.1 mEq/L and creatinine clearance of 45 mL/min. Which adjustment
is most appropriate?
Page 3
, Section A - Foundations OF Psychiatric Mental Health Nursing
A. Continue current dose and monitor renal B. Reduce lithium dose to 600 mg/day and
function monthly recheck level in 5 days
C. Discontinue lithium and start valproate D. Increase lithium dose to 1200 mg/day to
500 mg BID achieve therapeutic level
Correct: B - Reduce lithium dose to 600 mg/day and recheck level in 5 days
Rationale:With reduced creatinine clearance, lithium excretion is impaired, increasing toxicity
risk. Dose reduction is indicated. Continuing the current dose risks toxicity; discontinuing is
unnecessary; increasing dose is dangerous. Valproate could be considered if lithium is not
tolerated, but dose reduction is the first step.
Q4.
In the context of cognitive-behavioral therapy for panic disorder, which intervention is
primarily aimed at reducing interoceptive avoidance?
A. Creating a fear hierarchy of external B. Teaching diaphragmatic breathing for
situations relaxation
C. Conducting repeated exposure to feared D. Challenging catastrophic
bodily sensations misinterpretations of palpitations
Correct: C - Conducting repeated exposure to feared bodily sensations
Rationale:Interoceptive exposure involves repeated, systematic exposure to internal bodily
sensations (e.g., hyperventilation, spinning) to reduce fear of these sensations. Option A
targets situational avoidance, B is a relaxation technique, and D is cognitive restructuring,
which addresses misinterpretations but not avoidance directly.
Q5.
A patient with generalized anxiety disorder has not responded to first-line
pharmacotherapy. Which combination of psychotherapy and medication is most
supported by evidence for refractory cases?
A. Acceptance and commitment therapy B. Cognitive-behavioral therapy plus
plus buspirone pregabalin
C. Mindfulness-based stress reduction plus D. Interpersonal therapy plus duloxetine
hydroxyzine
Correct: B - Cognitive-behavioral therapy plus pregabalin
Rationale:CBT and pregabalin have strong evidence for GAD, including in refractory cases.
ACT and buspirone have less robust evidence; MBSR and hydroxyzine are less effective; IPT
is not indicated for GAD, and duloxetine is a first-line but not specifically for refractory cases
with CBT.
Page 4
